Drug Profile
HIV vaccine - Advanced BioScience Laboratories/NIAID
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Advanced BioScience Laboratories; National Institutes of Health (USA)
- Developer Advanced BioScience Laboratories
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections(Prevention) in USA (Parenteral)
- 03 Oct 2012 Advanced BioScience awards development and manufacturing contract to Avid Bioservices to support cGMP production of HIV gp145 envelope protein
- 11 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral Infections pharmacodynamics section